NovoCure (NVCR) Non-Current Deffered Revenue (2014 - 2023)

NovoCure has disclosed Non-Current Deffered Revenue across 9 years of filings, most recently posting $807000.0 for Q2 2023.

• Non-Current Deffered Revenue for Q2 2023 came in at $807000.0, down 82.23% year-over-year; the trailing twelve-month figure through Jun 2023 was $807000.0 (down 82.23% YoY), and the FY2022 annual result was $2.9 million, down 55.57% from the prior year.
• Non-Current Deffered Revenue came in at $807000.0 for Q2 2023 at NovoCure, down from $1.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $12.1 million in Q4 2020 to a low of $807000.0 in Q2 2023.
• The 5-year median for Non-Current Deffered Revenue is $7.9 million (2019), against an average of $7.0 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 55.49% in 2020 and sank 82.23% in 2023, its largest moves.
• NovoCure's Non-Current Deffered Revenue stood at $7.8 million in 2019, then surged by 55.49% to $12.1 million in 2020, then plunged by 46.64% to $6.5 million in 2021, then slumped by 55.57% to $2.9 million in 2022, then slumped by 71.96% to $807000.0 in 2023.
• The last three Non-Current Deffered Revenue figures came in at $807000.0 (Q2 2023), $1.8 million (Q1 2023), and $2.9 million (Q4 2022), per Business Quant data.